BYSL and glioma: The CCK-8 assay showed that silencing BYSL caused a significant decrease in the cell viability of glioma cells at 24 h (U251: P = 0.024; U87: P = 0.039), 48 h (U251: P = 0.002; U87: P = 0.051), and 72 h (U251: P = 0.005; U87: P = 0.019) (Figure 3A), and the cell viabilities of the U251 and U87 cells in the BYSL group were much higher than those in the vector group at 24, 48, and 72 h (U251: P = 0.003 at 24 and 48 h; P = 0.029 at 72 h; U87: all, P < 0.001) (Figure 3B).